Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis.
Journal of Affective Disorders October 12, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.
Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled...
DOI: 10.1016/j.jad.2026.122619 (opens in new tab)
Full text (opens in new tab)
Ketamine
Treatment-resistant depression
Augmentation strategies
Randomized controlled trials